LONA NASDAQ
LeonaBio, Inc.
1W: +45.5%
1M: -38.3%
3M: -45.5%
YTD: -32.0%
$4.73
+0.35 (+7.99%)
Weekly Expected Move ±28.1%
$2
$3
$5
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
20 relationships20
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2025-12-18
Earliest Filing
2026-03-31
Latest Filing
partner: 14
investor: 6
Counterparties (Filed by LONA)
20 relationshipsCompanies named in LONA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Sermonix Pharmaceuticals, Inc. | — | partner | Licensor of Lasofoxifene intellectual property and partner in the ELAINE-3 Study | 2026-03-31 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | partner | Counterparty to the Amended and Restated License Agreement with Sermonix | 2026-03-31 | View |
| Duke University | — | partner | Licensor of intellectual property to Sermonix under the Duke License Agreement | 2026-03-31 | View |
| Shanghai Henlius Biotech, Inc. | — | partner | Ex-Territory Licensee for Licensed Products | 2026-03-31 | View |
| Commodore Capital LP | — | investor | PIPE purchaser in private placement financing | 2025-12-18 | View |
| TCG Crossover Management LLC | — | investor | PIPE purchaser in private placement financing | 2025-12-18 | View |
| Perceptive Advisors | — | investor | PIPE purchaser and investment manager | 2025-12-18 | View |
| Eli Lilly & Co. | LLY | partner | Mentioned regarding FDA approval of imlunestrant in combination with abemaciclib | 2025-12-18 | View |
| Sermonix Pharmaceuticals, Inc. | — | partner | Licensee and counterparty in lasofoxifene license agreement | 2025-12-18 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | partner | Licensee and counterparty in lasofoxifene license agreement | 2025-12-18 | View |
| Shanghai Henlius Biotech, Inc. | — | partner | Exclusive licensee for lasofoxifene in Asia and Middle East | 2025-12-18 | View |
| Pfizer Inc. | PFE | partner | Original collaborator in discovery of lasofoxifene | 2025-12-18 | View |
| Commodore Capital LP | — | investor | PIPE purchaser in private placement financing | 2025-12-18 | View |
| TCG Crossover Management LLC | — | investor | PIPE purchaser in private placement financing | 2025-12-18 | View |
| Perceptive Advisors | — | investor | PIPE purchaser and investment manager | 2025-12-18 | View |
| Eli Lilly & Co. | LLY | partner | Mentioned regarding FDA approval of imlunestrant in combination with abemaciclib | 2025-12-18 | View |
| Sermonix Pharmaceuticals, Inc. | — | partner | Licensee and counterparty in lasofoxifene license agreement | 2025-12-18 | View |
| Ligand Pharmaceuticals Incorporated | LGNZZ | partner | Licensee and counterparty in lasofoxifene license agreement | 2025-12-18 | View |
| Shanghai Henlius Biotech, Inc. | — | partner | Exclusive licensee of lasofoxifene in Asia and certain Middle East countries | 2025-12-18 | View |
| Pfizer Inc. | PFE | partner | Original discoverer and developer of lasofoxifene | 2025-12-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-22 | Other Events | View | |
| 2026-08-26 | Other Events | View | |
| 2026-08-14 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-23 | Shareholder Vote | View | |
| 2026-03-31 | Acquisition/Disposition; Exhibits | Acquisition | View |
| 2026-03-26 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-01-09 | Departure/Election of Directors; Appointment of Officers; Amendments to Articles of Incorporation or | View | |
| 2025-12-18 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-12-18 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Regulation FD Dis | Agreement | View |
| 2025-11-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-03 | Other Events | View | |
| 2025-09-11 | Material Modification to Rights of Security Holders; Amendments to Articles of Incorporation or Byla | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-02 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-09 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-04-16 | Notice of Delisting or Transfer | View | |
| 2025-02-27 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-10-18 | Notice of Delisting or Transfer; Other Events | View | |
| 2024-10-07 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR